Shares of Novo Nordisk ( NVO 2.48%) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...

Analysts say this approval could significantly expand Alhemo's market potential. The hemophilia space is becoming ...

FDA approves Novo Nordisk's Alhemo for hemophilia A and B without inhibitors, following strong Phase 3 results showing reduced bleeding episodes.

Shares in Novo Nordisk fell as much as six per cent on Friday to their lowest since August 2021, extending recent losses to ...

FRANKFURT: European stocks logged their biggest one-day drop in over three months on Friday, at the end of a busy week as ...

All the health conditions weight-loss drugs are being used and tested for - Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some succe ...

Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...

Here are some of the major companies whose stocks moved on the week’s news.

This year's U.S. News & World Report list of top cancer hospitals includes MD Anderson Cancer Center, Memorial Sloan ...

NEW YORK — Wall Street’s record-breaking, weeklong run ran out of momentum on Tuesday. The S&P 500 slipped 0.3 per cent for ...

Global stocks weakened on Friday after Donald Trump hit dozens of countries with tariffs, as the US president pushed ahead ...